Hyundai Bioscience Co., Ltd. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was KRW 369.71 million compared to KRW 60 million a year ago. Net loss was KRW 20,051.09 million compared to KRW 8,259.9 million a year ago.

Basic loss per share from continuing operations was KRW 543 compared to KRW 230 a year ago. Diluted loss per share from continuing operations was KRW 543 compared to KRW 230 a year ago. Basic loss per share was KRW 543 compared to KRW 230 a year ago.